kabutan

Sumitomo Pharma, Apr-Dec (Cumulative 3Q) Net Income Increases by 5.1 times, Oct-Dec Net Income Decreases by 84%

Fri Jan 30, 2026 3:30 pm JST Earnings

4506 Sumitomo Pharma Co., Ltd. 【IFRS】

Earnings Report

Sumitomo Pharma Co., Ltd. <4506> [TSE Prime] announced its financial results (based on IFRS) after the market closed on January 30th (15:30). The consolidated net income for the cumulative third quarter of the fiscal year ending March 2026 (April to December) surged 5.1 times that of the same period last year, reaching 107 billion yen. Progress toward the full-year plan of 92.0 billion yen is 117.0%, already exceeding the target and also exceeding the five-year average of 99.0%.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net income/loss for the January to March period (4Q) is expected to turn into a loss of 15.6 billion yen (compared to a profit of 2.41 billion yen in the same period last year). However, if the fourth-quarter performance remains at the same level as the first three quarters, the full-year plan may be increased.

In the most recent three-month period, from October to December (3Q), the consolidated net income significantly dropped to 8.81 billion yen, an 83.5% decrease compared to the same period last year. The operating profit margin significantly dropped from 19.0% in the same period last year to 11.3%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2023 235,028 -117,745 -105,191 -117,708 -296.3 ー Jan 31, 2024 IFRS
Apr - Dec, 2024 293,183 13,226 24,026 21,219 53.4 136.4 Jan 31, 2025 IFRS
Apr - Dec, 2025 347,746 109,774 101,539 107,677 271.0 ー Jan 30, 2026 IFRS
YoY +18.6% +730.0% +322.6% +407.5% +407.5%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 218,083 36,983 50,017 55,863 140.6 0 May 13, 2025 IFRS
Oct - Mar, 2025 Guidance 201,878 1,843 ー -6,860 -17.3 0 Oct 31, 2025 IFRS
YoY -7.4% -95.0% － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 314,558 -354,859 -323,114 -314,969 -792.8 0 May 14, 2024 IFRS
Mar, 2025 398,832 28,804 17,611 23,634 59.5 0 May 13, 2025 IFRS
Mar, 2026 Guidance 429,000 98,000 ー 92,000 231.6 0 Oct 31, 2025 IFRS
YoY +7.6% +240.2% － +289.3% +289.3%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2024 112,434 21,405 56,432 53,448 134.5 19.0 Jan 31, 2025 IFRS
Jan - Mar, 2025 105,649 15,578 -6,415 2,415 6.1 14.7 May 13, 2025 IFRS
Apr - Jun, 2025 108,002 20,400 11,932 11,206 28.2 18.9 Jul 31, 2025 IFRS
Jul - Sep, 2025 119,120 75,757 80,870 87,654 220.6 63.6 Oct 31, 2025 IFRS
Oct - Dec, 2025 120,624 13,617 8,737 8,817 22.2 11.3 Jan 30, 2026 IFRS
YoY +7.3% -36.4% -84.5% -83.5% -83.5%

Related Articles